Cargando…

Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy

The elevation of SMN transcript and protein level remains the principal aim of SMA therapy. Still, there is no standard molecular biomarker for the assessment of its efficacy. In the current study, we tested three methods of SMN transcript level measurement using real-time RT-PCR, quantitative fluor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maretina, Marianna, Egorova, Anna, Lanko, Kristina, Baranov, Vladislav, Kiselev, Anton
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602009/ https://www.ncbi.nlm.nih.gov/pubmed/36292797 http://dx.doi.org/10.3390/genes13101911

Ejemplares similares

Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates
por: Maretina, Marianna A., et al.
Publicado: (2018)

Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III
por: Zheleznyakova, Galina Yu, et al.
Publicado: (2011)

Development of 2′-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells
por: Maretina, Marianna, et al.
Publicado: (2023)

Methylation Levels of SLC23A2 and NCOR2 Genes Correlate with Spinal Muscular Atrophy Severity
por: Zheleznyakova, Galina Yu., et al.
Publicado: (2015)

Peptide Nanoparticle-Mediated Combinatorial Delivery of Cancer-Related siRNAs for Synergistic Anti-Proliferative Activity in Triple Negative Breast Cancer Cells
por: Egorova, Anna, et al.
Publicado: (2021)

Magnetic Nanoparticles as a Component of Peptide-Based DNA Delivery System for Suicide Gene Therapy of Uterine Leiomyoma
por: Shtykalova, Sofia, et al.
Publicado: (2022)

Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen
por: Trifunov, Selena, et al.
Publicado: (2023)

Therapeutic strategies for spinal muscular atrophy: SMN and beyond
por: Bowerman, Melissa, et al.
Publicado: (2017)

SMN post-translational modifications in spinal muscular atrophy
por: Riboldi, Giulietta M., et al.
Publicado: (2023)

Molecular Crosstalk Between Non-SMN-Related and SMN-Related Spinal Muscular Atrophy
por: Šoltić, Darija, et al.
Publicado: (2020)

Characterization of iRGD-Ligand Modified Arginine-Histidine-Rich Peptides for Nucleic Acid Therapeutics Delivery to αvβ3 Integrin-Expressing Cancer Cells
por: Egorova, Anna, et al.
Publicado: (2020)

Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets
por: Tsai, Li-Kai
Publicado: (2012)

CORRIGENDUM to Molecular Crosstalk Between Non-SMN-Related and SMN-Related Spinal Muscular Atrophy
Publicado: (2020)

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)

SMN1 dosage analysis in spinal muscular atrophy from India
por: Kesari, Akanchha, et al.
Publicado: (2005)

Modeling spinal muscular atrophy in Drosophila links Smn to FGF signaling
por: Sen, Anindya, et al.
Publicado: (2011)

Deletion of SMN and NAIP genes in Korean patients with spinal muscular atrophy.
por: Shin, S., et al.
Publicado: (2000)

The Spinal Muscular Atrophy Disease Protein SMN Is Linked to the Golgi Network
por: Ting, Chen-Hung, et al.
Publicado: (2012)

25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy
por: Tiziano, Francesco Danilo, et al.
Publicado: (2020)

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
por: Valsecchi, Valeria, et al.
Publicado: (2023)

iRGD-Targeted Peptide Nanoparticles for Anti-Angiogenic RNAi-Based Therapy of Endometriosis
por: Egorova, Anna, et al.
Publicado: (2023)

Lysine-Less Variants of Spinal Muscular Atrophy SMN and SMNΔ7 Proteins Are Degraded by the Proteasome Pathway
por: Sánchez-Lanzas, Raúl, et al.
Publicado: (2017)

Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: a promising target for spinal muscular atrophy therapeutics
por: Dayangac-Erden, Didem, et al.
Publicado: (2011)

Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies
por: Peeters, Kristien, et al.
Publicado: (2014)

Deletion analysis of SMN and NAIP genes in Tunisian patients with spinal muscular atrophy
por: Rekik, Imen, et al.
Publicado: (2013)

Targeting SR Proteins Improves SMN Expression in Spinal Muscular Atrophy Cells
por: Wee, Claribel D., et al.
Publicado: (2014)

SMN-primed ribosomes modulate the translation of transcripts related to Spinal Muscular Atrophy
por: Lauria, Fabio, et al.
Publicado: (2020)

Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy
por: Wadman, Renske I, et al.
Publicado: (2020)

The Importance of Digging into the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy
por: Costa-Roger, Mar, et al.
Publicado: (2021)

Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy
por: Aslesh, Tejal, et al.
Publicado: (2022)

NSC Physiological Features in Spinal Muscular Atrophy: SMN Deficiency Effects on Neurogenesis
por: Adami, Raffaella, et al.
Publicado: (2022)

Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma
por: Egorova, Anna, et al.
Publicado: (2021)

SAM68 is a physiological regulator of SMN2 splicing in spinal muscular atrophy
por: Pagliarini, Vittoria, et al.
Publicado: (2015)

Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes
por: Garcia-Lopez, Amparo, et al.
Publicado: (2018)

Stability and Oligomerization of Mutated SMN Protein Determine Clinical Severity of Spinal Muscular Atrophy
por: Niba, Emma Tabe Eko, et al.
Publicado: (2022)

Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy
por: Comley, Laura H, et al.
Publicado: (2022)

Molecular characterization and copy number of SMN1, SMN2 and NAIP in Chinese patients with spinal muscular atrophy and unrelated healthy controls
por: Fang, Ping, et al.
Publicado: (2015)

Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development
por: Butchbach, Matthew E. R.
Publicado: (2021)

Polycondensed Peptide Carriers Modified with Cyclic RGD Ligand for Targeted Suicide Gene Delivery to Uterine Fibroid Cells
por: Egorova, Anna, et al.
Publicado: (2022)

A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2
por: Jodelka, Francine M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_un3ovdb27jrth6bmf66f0ku7lr